Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: A 20-year experience

International Journal of Gynecological Cancer

Volumn 19, Issue 6, 2009, Pages 1080-1084

  Mahdavi, Ali ^a   Monk, Bradley J ^a   Ragazzo, Jennifer ^a   Hunter, Mark I ^a   Lentz, Scot E ^b   Vasilev, Steven A ^b   Tewari, Krishnansu S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Pelvic radiation; Uterine leiomyosarcoma

Indexed keywords

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; KAPLAN MEIER METHOD; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; UTERUS LEIOMYOSARCOMA;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; HYSTERECTOMY; LEIOMYOSARCOMA; MIDDLE AGED; PELVIS; PROGNOSIS; RADIOTHERAPY; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; UTERINE NEOPLASMS;

EID: 70349244794     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181acae50     Document Type: Article

References (24)

1. Mayerhofer K, Obermair A, Windbichler G, et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol. 1999;74:196-201.
2. Hannigan EV, Gomez LG. Uterine leiomyosarcoma. Am J Obstet Gynecol. 1979;134:557-564.
3. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71:1702-1709.
4. Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys. 1986;12:2127-2130.
5. Dusenbery KE, Potish RA, Argenta PA, et al. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol. 2005;28:295Y300.
6. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley; 1980.
7. Liang KY, Self SG, Bandeen-Roche KJ, et al. Some recent developments for regression analysis of multivariate failure time data. Lifetime Data Anal. 1995;1:403-415.
8. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744-751.
9. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;22;355:1404-1411.
10. Kal HB, Hahn GM. Kinetic responses of murine sarcoma cells to radiation and hyperthermia in vivo and in vitro. Cancer Res. 1976;36:1923-1929.
11. Kelland LR, Bingle L. Radiosensitivity and characterisation of a newly established cell line from an epithelioid sarcoma. Br J Cancer. 1988;58:322-325.
12. Damjanov I, Casey MJ, Maenza RM, et al. Mullerian adenosarcoma of the uterus. Ultrastructure before and after radiation therapy. Am J Clin Pathol. 1978;70:96-103.
13. Livi L, Paiar F, Shah N, et al. Uterine sarcoma: twenty-seven years of experience. Int J Radiat Oncol Biol Phys. 2003;57:1366-1373.
14. Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89:460-469.
15. Echt G, Jepson J, Steel J, et al. Treatment of uterine sarcomas. Cancer. 1990;66:35-39.
16. Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004;93:204-208.
17. Livi L, E. Andreopoulou E, Shah N, et al. Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998. Clin Oncol. 2004;16:261-268.
18. Gerszten K, Faul C, Kounelis S, et al. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol. 1998; 68:8-13.
19. Knocke TH, Kucera H, Dorfler D, et al. Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer. 1998;83:1972-1979.
20. Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44:808-818.
21. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824-2831.
22. Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18:2081-2086.
23. Fields AL, Einstein MH, Novetsky AP, et al. Pilot phase II trial of radiation Bsandwiched[ between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2008;108:201-206.
24. Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol. 2009; [Epub ahead of print].